Eupraxia Pharmaceuticals (EPRX) Research & Development (2023 - 2026)
Eupraxia Pharmaceuticals' Research & Development came in at $12.81 million for Q2 2026, up 146.4% from $5.2 million a year earlier and up 14.6% from the prior quarter.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Research & Development (2023 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Eupraxia Pharmaceuticals reported Research & Development of $36.26 million, up 113.6% year-over-year; for FY2025, it came in at $21.33 million, up 32.7% from FY2024.
- Research & Development carries a three-year compound annual growth rate of 16.1% (FY2022 to FY2025).
- Going back by year, Research & Development was $16.08 million in FY2024 (-21.0%), $20.36 million in FY2023 (+49.4%) and $13.63 million in FY2022.
- The Q2 2026 figure represents the highest quarterly Research & Development in data going back to Q1 2023.
- Year-over-year, Research & Development has increased for five consecutive quarters, with growth averaging 49.7% over the last eight quarters.
- The fastest year-over-year change in Research & Development over five years came in Q1 2026 (growth of 190.2%), and the weakest in Q4 2024 (a decline of 59.3%).
- Business Quant data shows EPRX's Research & Development at $11.17 million (Q1 2026), $7.87 million (Q4 2025) and $4.42 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 3.89 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.02 Bn |
| 10 | Eupraxia Pharmaceuticals | 304.87 Mn | -174.66 Mn | - | 10.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 10.82 Mn |
| Jun 30, 2026 | 12.81 Mn |
| Mar 31, 2026 | 11.17 Mn |
| Dec 31, 2025 | 7.87 Mn |
| Sep 30, 2025 | 4.42 Mn |
| Jun 30, 2025 | 5.20 Mn |
| Mar 31, 2025 | 3.85 Mn |
| Dec 31, 2024 | 3.88 Mn |
| Sep 30, 2024 | 4.05 Mn |
| Jun 30, 2024 | 3.97 Mn |
| Mar 31, 2024 | 4.18 Mn |
| Dec 31, 2023 | 9.54 Mn |
| Sep 30, 2023 | 4.76 Mn |
| Jun 30, 2023 | 3.79 Mn |
| Mar 31, 2023 | 2.27 Mn |
API Access
Eupraxia Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=EPRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "EPRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=EPRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();